Microsporidia spore

Microsporidia spores represent the dormant, highly resilient infectious stage of Microsporidia, a group of obligate intracellular parasitic fungi. These spores are characterized by a unique infection mechanism involving a specialized organelle called the polar tube, which, upon germination, pierces the host cell membrane to inject the parasite's sporoplasm. While the spore itself is a biological entity and not a single molecular target, it contains several therapeutic targets such as beta-tubulin and methionine aminopeptidase 2 (MetAP2). Microsporidiosis, the disease caused by these spores, is most prevalent in immunocompromised individuals, leading to chronic diarrhea, wasting, and disseminated infections. Current pharmacological strategies focus on disrupting the structural integrity of the parasite or its metabolic enzymes to halt the transition from the spore stage to the proliferative stage within the host.

Other names

Microsporidian sporeMicrosporidiaEnterocytozoon bieneusi sporeEncephalitozoon cuniculi sporeNosema spore

Drugs targeting Microsporidia generally act by inhibiting tubulin polymerization (e.g., Albendazole) or by inhibiting methionine aminopeptidase 2 (MetAP2) (e.g., Fumagillin), which prevents protein processing and parasite replication within the host cell after spore germination.